利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.027 秒)

    Identifying peptides having T-cell-exposed motifs with known frequency of occurrence in a reference database
    2.
    发明授权
    Identifying peptides having T-cell-exposed motifs with known frequency of occurrence in a reference database 有权

    公开(公告)号：US10755801B2

    公开(公告)日：2020-08-25

    申请号：US15325655

    申请日：2015-07-10

    申请人： IOGENETICS, LLC

    发明人： Robert D. Bremel ,  Jane Homan ,  Michael Imboden

    IPC分类号： G16B30/00 ,  G16B20/00 ,  G16B50/00 ,  G01N33/68

    摘要： The present invention provides methods and systems for identifying and classifying epitopes and use of that information to analyze proteins and peptides within proteins, especially potential epitopes, and to use the information to design synthetic peptides and proteins, analyze biopharmaceutical proteins, and diagnose autoimmune conditions. Peptides which are bound in MHC grooves comprise two sets of amino acids: those that face inwards into the groove and determine the binding affinity to the MHC molecule (the groove exposed motifs or GEM) and those which do not interact with the groove but rather are on the obverse side exposed outwardly to the T-cells (the T-cell exposed Motifs or TCEM). The present invention utilizes information related to the identity and physiochemical characteristics of the GEM and TCEM.

    Mathematical processes for determination of peptidase cleavage
    5.
    发明授权
    Mathematical processes for determination of peptidase cleavage 有权

    公开(公告)号：US11069427B2

    公开(公告)日：2021-07-20

    申请号：US14895748

    申请日：2014-06-09

    申请人： IOGENETICS, LLC

    发明人： Robert D. Bremel

    IPC分类号： G16B20/00 ,  G16B5/00 ,  G16B40/00 ,  G06N3/04 ,  G06N3/08

    摘要： This invention relates to the identification of peptidase cleavage sites in proteins and in particular to identification protease cleavage by the endopeptidases. The present invention utilizes a bioinformatic methodology for prediction of peptidase cleavage sites based on principal component analysis and based on training sets obtained by experimental protein cleavage. This invention is not limited to training sets derived from CSL approaches, nor to any other experimental determination of cleavage site.

    Innate Immune Receptor Directed Biocides
    8.
    发明申请
    Innate Immune Receptor Directed Biocides 审中-公开
    先天免疫受体导向杀生物剂

    公开(公告)号：US20080267943A1

    公开(公告)日：2008-10-30

    申请号：US11875343

    申请日：2007-10-19

    申请人： Michael Imboden ,  Jane Homan ,  Robert D. Bremel

    发明人： Michael Imboden ,  Jane Homan ,  Robert D. Bremel

    IPC分类号： A61K38/43 ,  A61K38/00 ,  C12N5/06 ,  C12N15/00 ,  A01K67/027 ,  A61P31/00 ,  A23L3/3463

    CPC分类号： A01N63/04 ,  A01N63/00 ,  A01N63/02 ,  A01N65/00 ,  C07K16/00 ,  C07K16/20 ,  C07K2317/52 ,  C07K2319/01 ,  C07K2319/035 ,  C07K2319/33 ,  C07K2319/55 ,  C07K2319/735

    摘要： The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense.

    摘要翻译： 本发明涉及编码新单克隆抗体，新型融合蛋白和嵌合单克隆抗体的逆转录病毒构建体及其使用和生产方法。 特别地，本发明涉及在转基因动物（例如牛）和细胞中产生包含微生物靶向分子（例如，免疫球蛋白或先天免疫系统受体分子）和杀生物剂（例如杀菌酶）的融合蛋白的方法。 文化。 本发明还涉及在医疗保健（例如人类和兽医），农业（例如动物和植物生产）和食品加工（例如，动物和植物生产）中使用包含微生物靶向分子和杀生物剂的融合蛋白的治疗和预防方法， 牛肉屠体处理）。 本发明还涉及在农业，医药，国防等不同领域的多种诊断应用中使用包含微生物靶向分子和杀生物剂的融合蛋白的方法。

    PERSONALIZED ALLOGENEIC IMMUNOTHERAPY
    10.
    发明公开
    PERSONALIZED ALLOGENEIC IMMUNOTHERAPY 审中-公开

    公开(公告)号：US20240197878A1

    公开(公告)日：2024-06-20

    申请号：US18287715

    申请日：2022-04-20

    申请人： IOGENETICS, LLC

    发明人： Jane Homan ,  Robert D. Bremel

    IPC分类号： A61K39/00 ,  A61P35/00 ,  C12N15/10 ,  G16B15/30 ,  G16B20/20

    CPC分类号： A61K39/464401 ,  A61K39/4611 ,  A61P35/00 ,  C12N15/1055 ,  G16B15/30 ,  G16B20/20

    摘要： The present invention provides methods for treating cancer by T cell therapy comprising the steps of obtaining a biopsy from a subject affected by cancer, identifying mutated amino acids in the tumor and the T cell exposed amino acid motifs which contain the mutated amino acids, identifying a donor with matching alleles, generating an array of alternate peptides in which the T cell exposed motifs are maintained constant, but the other amino acids are substituted, selecting one or more peptides from the array of alternative peptides, each having a desired binding affinity to the MHC allele while maintaining the tumor specific T cell exposed motif, contacting antigen presenting cells with the selected alternative peptides so that the peptide is presented by the MHC of the antigen presenting cells, contacting the antigen presenting cells carrying the selected peptide with T cells harvested from the donor, and infusing the subject with stimulated T cells responding to the peptide of interest presented by the dendritic cell MHC.